A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Exclusion Criteria

• •Progressed while on temozolomide
• •Evidence of acute intracranial or intratumoral hemorrhage \> Grade 1
• •Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including cytotoxic chemotherapy other than temozolomide, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents, prior therapy with a PI3K inhibitors, radiation therapy, enzyme-inducing anti-convulsants, valproic acid
• •Not recovered from the toxic effects of prior therapy
• •Pregnant or breast feeding
• •History of diabetes mellitus
• •Uncontrolled intercurrent illness
• •Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.
• •HIV positive
• •Diagnosis of another malignancy may exclude subject from study